中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.028 seconds)

    Compositions and methods for modulating serum cholesterol
    11.
    发明申请
    Compositions and methods for modulating serum cholesterol 审中-公开
    用于调节血清胆固醇的组合物和方法

    公开(公告)号：US20050079998A1

    公开(公告)日：2005-04-14

    申请号：US10640502

    申请日：2003-08-13

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: A61K38/46 ,  A61K38/57 ,  G01N33/92 ,  A61K38/00 ,  A61K31/366 ,  A61K31/401 ,  A61K31/685

    CPC classification number: G01N33/92 ,  A61K31/164 ,  A61K38/1709 ,  G01N2800/044 ,  A61K2300/00

    Abstract: Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.

    Abstract translation: 提供了用于调节受试哺乳动物血清胆固醇的组合物和方法。 一方面，本发明的特征在于新型抗血脂药物，其包括至少一种鉴定的低密度脂蛋白（LDL）受体的效应物和至少一种鉴定的血清胆固醇抑制剂。 在一个特定方面，所述药物包括与所鉴定的一种血清胆固醇抑制剂相连的一种鉴别的鞘脂或蛋白质修饰。 另外提供了用于鉴定能够调节LDL受体和特异性SREBP-1成熟的抗血脂药物的方法，包括设计用于鉴定能够稳定或降低哺乳动物，特别是人类患者血清胆固醇水平的药理学药物的测定法。

    NOVEL APOC-I ISOFORMS AND THEIR USE AS BIOMARKERS AND RISK FACTORS OF ATHEROSCLEROTIC DISEASE
    16.
    发明申请
    NOVEL APOC-I ISOFORMS AND THEIR USE AS BIOMARKERS AND RISK FACTORS OF ATHEROSCLEROTIC DISEASE 审中-公开
    新型APOC-I ISOFORMS及其作为生物标志物和ATHEROSCLEROTIC DISEASE的风险因素

    公开(公告)号：US20140193846A1

    公开(公告)日：2014-07-10

    申请号：US14112670

    申请日：2011-12-23

    Applicant: Ronald D. Macfarlane ,  Catherine J. McNeal ,  Subroto Chatterjee

    Inventor： Ronald D. Macfarlane ,  Catherine J. McNeal ,  Subroto Chatterjee

    IPC: G01N33/92

    CPC classification number: G01N33/92 ,  C07K14/775 ,  G01N2800/324 ,  G01N2800/50

    Abstract: Novel isoforms of apolipoprotein C-I (apoC-I), namely apolipoprotein C-I1 (apoC-I1) and apolipoprotein C-I1′ (apoC-I1′), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein C-I (SEQ ID NO:6) and native apolipoprotein C-I′ (SEQ ID NO:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.

    Abstract translation: 载脂蛋白C1（apoC-I），即载脂蛋白C-I1（apoC-I1）和载脂蛋白C-I1'（apoC-I1'）的新型同工型，其分子量比天然载脂蛋白CI大约为90道尔顿 （SEQ ID NO：6）和天然载脂蛋白C1'（SEQ ID NO：7）显示为用于诊断动脉粥样硬化疾病的生物标志物以及具有发展动脉粥样硬化疾病风险增加的受试者的危险因素。

    Methods of diagnosing atherosclerosis by measuring ApoCI
    18.
    发明授权
    Methods of diagnosing atherosclerosis by measuring ApoCI 有权
    通过测量ApoCI来诊断动脉粥样硬化的方法

    公开(公告)号：US08614064B2

    公开(公告)日：2013-12-24

    申请号：US10557283

    申请日：2004-05-24

    Applicant: Subroto Chatterjee ,  Peter O. Kwiterovich

    Inventor： Subroto Chatterjee ,  Peter O. Kwiterovich

    IPC: G01N33/53 ,  C07K14/775

    CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2800/323 ,  G01N2800/324

    Abstract: The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.

    Abstract translation: 本发明提供用于鉴定抑制ApoCI并可用于治疗或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的化合物的方法和组合物。 本发明还提供了治疗患有或具有发展动脉粥样硬化，斑块破裂，凋亡或心肌梗塞的风险的受试者的方法。 本发明还提供了用于诊断患有或处于或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的受试者的方法。

    Compositions and methods for modulating serum cholesterol
    20.
    发明授权
    Compositions and methods for modulating serum cholesterol 失效
    用于调节血清胆固醇的组合物和方法

    公开(公告)号：US06713057B1

    公开(公告)日：2004-03-30

    申请号：US09511532

    申请日：2000-02-23

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: A61K3846

    CPC classification number: G01N33/92 ,  A61K31/164 ,  A61K38/1709 ,  G01N2800/044 ,  A61K2300/00

    Abstract: Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.

    Abstract translation: 提供了用于调节受试哺乳动物血清胆固醇的组合物和方法。 一方面，本发明的特征在于新型抗血脂药物，其包括至少一种鉴定的低密度脂蛋白（LDL）受体的效应物和至少一种鉴定的血清胆固醇抑制剂。 在一个特定方面，所述药物包括与所鉴定的一种血清胆固醇抑制剂相连的一种鉴别的鞘脂或蛋白质修饰。 另外提供了用于鉴定能够调节LDL受体和特异性SREBP-1成熟的抗血脂药物的方法，包括设计用于鉴定能够稳定或降低哺乳动物，特别是人类患者血清胆固醇水平的药理学药物的测定法。

Patent Agency Ranking